Andrew Cleeland

The Fogarty Institute for Innovation: Supporting Innovation in Medtech

Andrew Cleeland

Talk: The Fogarty Institute for Innovation: Supporting Innovation in Medtech

Medtech startups face multiple risks and challenges as they struggle to bring their products to market, which means many live-saving technologies never reach patients in need. For this reason, the Darwinian/survival-of-the-fittest environment that tech startups typically compete within can be counterproductive for the medtech industry and patients - as the most beneficial technologies don’t always survive. The Fogarty Institute for Innovation, a nonprofit based in Silicon Valley, has created a non-Darwinian environment where medtech startups are given time, space & support to survive & thrive as independent companies in the risk intensive medtech ecosystem. The panel includes: Andrew Cleeland, Anne Morrissey, Sergio Aguirre, & Shin Kosuga

Andrew Cleeland

Andrew Cleeland is an executive with 27 years in medtech in both private and public sector roles. Andrew is currently Vice President/General Manager of Medtronic’s Transcatheter Mitral Valve Venture following its recent acquisition of Twelve Inc., where he was the president and CEO. Prior to Twelve, he was the president and CEO of Ardian.